A Randomised Trial Comparing Anterior Versus Posterior Approach in Total Hip Replacement

Medacta

Status

Completed

Conditions

Osteoarthritis

Rheumatoid Arthritis

Treatments

Procedure: Standard postero-lateral approach

Procedure: Minimally Invasive Anterior Approach

Study type

Interventional

Funder types

Industry

Identifiers

NCT01106560

P01.004.12 rev.01

Details and patient eligibility

About

This is a single-centre, randomised, prospective clinical follow-up study to evaluate clinical outcome and gait analysis after total hip arthroplasty using the standard postero-lateral approach or the minimally invasive anterior approach.

Enrollment

50 patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Males and females aged 18-75 years at time of surgery.
Those presenting with primary or secondary osteoarthritis and/or rheumatoid arthritis of the hip.
Those deemed capable of giving informed consent, understanding the aims of the study and expressing willingness to comply with the post-operative review programme.
Patients who signed the study consent form prior to surgery.

Exclusion criteria

Pregnant women or women who plan to conceive in the future.
Those whose prospects for a recovery to independent mobility would be compromised by known coexistent, medical problems.
Those already treated by with a Total Hip Replacement (THR) (i.e. requiring a revision hip replacement).
Those with co-existent ipsilateral knee disease or back problems
Muscle contracture around the hip joint
Individuals who have undergone organ transplant.
Those with a known co-existent medical condition where death is anticipated within five years due to the pre-existing medical condition.
Individuals who have had a THR on the contra-lateral side within the 6 months.
Individuals who have undergone a THR on the contralateral side and whose outcome is considered unsatisfactory or not good. An unsatisfactory or poor result is defined as achieving a total UCLA score (including activity) < 16 points.
Individuals requiring bilateral hip replacement.
Individuals whose body mass index (BMI; kg/m2) >35.
Individuals with active or suspected infection or sepsis.
Individuals with renal failure and/or renal insufficiency.
Patients with severe forms of developmental dysplasia of the hip (DDH): Crowe types II, III, IV.